Factors associated with fingolimod rebound: A single center real-life experience

Goncuoglu C., Tuncer A., Bayraktar-Ekincioglu A., Cagan C. A., Acar-Ozen P., ÇAKAN M., ...More

MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.56, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 56
  • Publication Date: 2021
  • Doi Number: 10.1016/j.msard.2021.103278
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Keywords: Fingolimod, Discontinuation, Rebound, Multiple Sclerosis, Washout, Disease modifying therapy, MULTIPLE-SCLEROSIS, DISEASE REACTIVATION, WITHDRAWAL, DISCONTINUATION, CESSATION
  • Hacettepe University Affiliated: Yes


Background It is still controversial whether the relapse experienced after discontinuation of fingolimod treatment is a rebound. Increasing cases of rebound have been reported in the literature. The rate of fingolimod rebound in patients after fingolimod cessation is reported between 5% and 52%. The present study aims to determine the rate of rebound after discontinuation of fingolimod treatment and the factors affecting the rebound. Methods This retrospective cohort study consists of adult MS patients who have been admitted to the Hacettepe University Hospital Neurology MS Center outpatient clinic between 2012 and 2020. Results During the study period, 642 patients received fingolimod and 23.1% discontinued the fingolimod treatment. Thirteen of 126 patients had a rebound (10.3%) after fingolimod discontinuation. The patients in the rebound group were significantly younger and washout period were significantly longer than those in the non rebound group. After discontinuation of fingolimod treatment, the EDSS score of the rebound group was significantly higher than the non-rebound group, while Annualized Relapse Rates were similar. Conclusion Younger age, longer washout time, and previous treatment preferences may increase the occurrence probability of rebound. It is recommended that patients should be closely monitored after fingolimod discontinuation and appropriate disease-modifying therapy should be initiated as soon as possible.